Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (4404)	5/24/2003 9:43:44 AM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Rob >> Comparison of phase II results might indicate a significant difference in effectiveness>> You mean assuming that the two companies have irred at the same level and with the same severity, when designing their phase II trials. And underpowered their studies to the same extent? What is your opinion by the way about Antegren missing its primary endpoint in the phase II Crohn's trial? Should this be held against the drug or not when such a comparison as you suggest is done? Erik